Welcome to LookChem.com Sign In|Join Free
  • or
2-(1,3-benzodioxol-5-yl)ethyl acetate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

85263-29-2

Post Buying Request

85263-29-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

85263-29-2 Usage

Usage

Flavoring agent in the food industry

Aroma

Sweet and spicy, reminiscent of sassafras and black licorice

Precursor

Illegal manufacture of the drug MDMA (ecstasy)

Regulatory status

Highly regulated and restricted in many countries due to the carcinogenic properties of its precursor, safrole.

Check Digit Verification of cas no

The CAS Registry Mumber 85263-29-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,5,2,6 and 3 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 85263-29:
(7*8)+(6*5)+(5*2)+(4*6)+(3*3)+(2*2)+(1*9)=142
142 % 10 = 2
So 85263-29-2 is a valid CAS Registry Number.

85263-29-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(1,3-benzodioxol-5-yl)ethyl acetate

1.2 Other means of identification

Product number -
Other names <3,4-Methylendioxy-phenaethyl>-acetat

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:85263-29-2 SDS

85263-29-2Downstream Products

85263-29-2Relevant academic research and scientific papers

Sulfonamides for treatment of endothelin-mediated disorders

-

, (2008/06/13)

Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of endothelin diseases using these formulations and sulfonamides a

Sulfonamides for treatment of endothelin-mediated disorders

-

, (2008/06/13)

Thienyl-, furyl- and pyrrolyl-sulfonamides, pharmaceutically-acceptable salts of sulfonamides, formulations of salts and the sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations and

Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

-

, (2008/06/13)

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

-

Page column 122, (2010/01/30)

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Formulation of sulfonamides for treatment of endothelin-mediated disorders

-

, (2008/06/13)

Formulations of pharmaceutically-acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides using the formulations are provided. In particular, formulations of so

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 85263-29-2